Yi Hu Selected Research

Brain Neoplasms (Brain Tumor)

1/2023	Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases.
1/2020	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
10/2018	Early versus late prophylactic cranial irradiation in patients with extensive small cell lung cancer.
12/2016	Prophylactic cranial irradiation could improve overall survival in patients with extensive small cell lung cancer : A retrospective study.
7/2012	Arg9 facilitates the translocation and downstream signal inhibition of an anti-HER2 single chain antibody.
12/2007	(99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yi Hu Research Topics

Disease

214	Neoplasms (Cancer) 04/2024 - 01/2003
68	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 03/2006
39	Neoplasm Metastasis (Metastasis) 04/2024 - 08/2006
37	Infections 02/2024 - 10/2009
28	Lung Neoplasms (Lung Cancer) 02/2024 - 07/2007
26	Esophageal Squamous Cell Carcinoma 03/2024 - 01/2009
25	Inflammation (Inflammations) 05/2024 - 10/2016
25	Adenocarcinoma of Lung 01/2023 - 11/2007
24	Carcinoma (Carcinomatosis) 11/2023 - 01/2003
19	Esophageal Neoplasms (Esophageal Cancer) 02/2024 - 11/2005
18	Glioma (Gliomas) 11/2021 - 12/2007
16	Breast Neoplasms (Breast Cancer) 10/2022 - 01/2002
15	COVID-19 01/2024 - 01/2020
14	Pneumonia (Pneumonitis) 11/2023 - 01/2017
12	Tuberculosis (Tuberculoses) 11/2023 - 11/2009
11	Carcinogenesis 01/2024 - 10/2016
11	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2024 - 11/2015
11	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 10/2008
11	Stomach Neoplasms (Stomach Cancer) 01/2023 - 01/2014
10	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2024 - 06/2008
10	Sepsis (Septicemia) 01/2024 - 10/2020
9	Disease Progression 02/2024 - 09/2011
9	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2023 - 11/2004
8	Adenocarcinoma 01/2023 - 08/2010
8	Melanoma (Melanoma, Malignant) 01/2022 - 01/2014
8	Hemorrhagic Shock 01/2020 - 01/2011
7	Wounds and Injuries (Trauma) 04/2024 - 08/2010
7	Hemorrhage 11/2023 - 01/2013
7	Lymphatic Metastasis 09/2023 - 02/2010
7	Shock 07/2019 - 02/2011
6	Hypoxia (Hypoxemia) 10/2023 - 01/2008
6	Triple Negative Breast Neoplasms 10/2023 - 01/2019
6	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 01/2019
6	Brain Neoplasms (Brain Tumor) 01/2023 - 12/2007
6	Pathologic Constriction (Stenosis) 01/2017 - 01/2003
5	Asthma (Bronchial Asthma) 10/2023 - 10/2015
5	Bacterial Infections (Bacterial Infection) 08/2023 - 05/2011
5	Pain (Aches) 02/2023 - 01/2017
5	Alzheimer Disease (Alzheimer's Disease) 12/2022 - 04/2012
5	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 10/2011
5	Parkinson Disease (Parkinson's Disease) 11/2021 - 04/2010
5	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 01/2015

Drug/Important Bio-Agent (IBA)

48	Proteins (Proteins, Gene)FDA Link 02/2024 - 01/2002
40	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2017
40	Biomarkers (Surrogate Marker)IBA 02/2024 - 09/2011
20	Messenger RNA (mRNA)IBA 05/2024 - 06/2005
20	MicroRNAs (MicroRNA)IBA 04/2024 - 06/2011
15	Long Noncoding RNAIBA 02/2024 - 08/2015
13	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2024 - 01/2016
13	RNA (Ribonucleic Acid)IBA 01/2024 - 01/2017
12	Therapeutic UsesIBA 03/2024 - 12/2007
12	CytokinesIBA 11/2023 - 10/2009
12	AntigensIBA 09/2023 - 12/2005
12	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 03/2006
11	Indicators and Reagents (Reagents)IBA 02/2024 - 11/2007
11	ErbB Receptors (EGF Receptor)IBA 11/2023 - 09/2011
11	CateninsIBA 01/2023 - 11/2010
9	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2023 - 01/2002
9	Oxygen (Dioxygen)IBA 10/2023 - 02/2014
9	VaccinesIBA 09/2023 - 01/2019
9	Peptides (Polypeptides)IBA 01/2023 - 03/2014
8	AntibodiesIBA 09/2023 - 05/2009
8	Tyrosine Kinase InhibitorsIBA 07/2023 - 01/2014
7	LipidsIBA 11/2023 - 01/2021
7	PlatinumIBA 12/2020 - 10/2006
6	LipopolysaccharidesIBA 05/2024 - 01/2018
6	1- (5- (2- fluorophenyl)- 1- (pyridin- 3- ylsulfonyl)- 1H- pyrrol- 3- yl)- N- methylmethanamineIBA 02/2024 - 01/2017
6	Glucose (Dextrose)FDA LinkGeneric 02/2024 - 01/2023
6	Antiviral Agents (Antivirals)IBA 12/2023 - 01/2018
6	Chimeric Antigen ReceptorsIBA 07/2023 - 01/2015
6	AlbuminsIBA 04/2023 - 03/2018
6	AntioxidantsIBA 03/2023 - 01/2016
6	pembrolizumabIBA 02/2023 - 01/2017
6	Bevacizumab (Avastin)FDA Link 01/2022 - 01/2014
6	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 08/2010
6	Small Interfering RNA (siRNA)IBA 10/2021 - 01/2013
5	Circular RNAIBA 04/2024 - 01/2020
5	Amoxicillin (Wymox)FDA LinkGeneric 02/2024 - 01/2022
5	EnzymesIBA 02/2024 - 01/2016
5	FlavonoidsIBA 01/2024 - 01/2022
5	130-nm albumin-bound paclitaxelIBA 04/2023 - 08/2015
5	LigandsIBA 12/2022 - 09/2011
5	fibrin fragment D (D-dimer)IBA 10/2022 - 07/2016
5	Programmed Cell Death 1 ReceptorIBA 01/2022 - 01/2020
5	Immunoglobulin G (IgG)IBA 01/2021 - 12/2010
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 03/2009
5	Pemetrexed (MTA)FDA Link 01/2021 - 05/2010
5	Monoclonal AntibodiesIBA 12/2020 - 02/2012

Therapy/Procedure

117	Therapeutics 05/2024 - 01/2003
67	Drug Therapy (Chemotherapy) 02/2024 - 01/2003
35	Immunotherapy 02/2024 - 10/2013
19	Esophagectomy 01/2024 - 01/2006
14	Radiotherapy 03/2024 - 01/2003
9	Neoadjuvant Therapy 12/2023 - 11/2004
7	Stents 11/2023 - 01/2006
7	Aftercare (After-Treatment) 10/2023 - 10/2011
6	Length of Stay 10/2023 - 01/2019
6	Precision Medicine 01/2023 - 01/2017
5	Lymph Node Excision (Lymph Node Dissection) 02/2024 - 08/2010
5	Lasers (Laser) 02/2023 - 04/2015